OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in Rheumatology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
COVID-19 and autoimmune diseases	356
The role of diet in hyperuricemia and gout	69
Recent advances in targeted drug delivery for treatment of osteoarthritis	59
Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate	59
Racial, ethnic, and healthcare disparities in rheumatoid arthritis	51
The role of CD8+ T-cell systemic lupus erythematosus pathogenesis: an update	45
Double-negative T cells in autoimmune diseases	45
Contribution of monocytes and macrophages to the pathogenesis of systemic sclerosis: recent insights and therapeutic implications	45
Osteoporosis and fractures in rheumatoid arthritis	43
The association of Behçet's syndrome with HLA-B51 as understood in 2021	39
COVID-19 and rheumatoid arthritis	35
Inflammation in osteoarthritis: the latest progress and ongoing challenges	35
Blood and urine biomarkers in osteoarthritis – an update on cartilage associated type II collagen and aggrecan markers	33
Cellular aspects of the pathogenesis of lupus nephritis	33
Telerheumatology: before, during, and after a global pandemic	33
Interstitial lung disease throughout the rheumatoid arthritis disease course	30
Treatment for systemic sclerosis-associated interstitial lung disease	30
Role of adipose tissues in osteoarthritis	26
Scleroderma epidemiology update	25
Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy	24
Lymphocyte immunophenotyping in inflammatory myositis: a review	23
Cryoglobulinemic vasculitis: pathophysiological mechanisms and diagnosis	23
Update on gout management: what is old and what is new	23
Gastrointestinal involvement in systemic sclerosis: pathogenesis, assessment and treatment	21
B cells in systemic lupus erythematosus	20

Update in familial Mediterranean fever	20
Insights into the molecular landscape of osteoarthritis in human tissues	19
Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit	19
Diagnostic, predictive and prognostic biomarkers in systemic lupus erythematosus: current insights	18
Pathogenesis of lupus nephritis: the contribution of immune and kidney resident cells	18
Posttraumatic osteoarthritis: what have we learned to advance osteoarthritis?	17
Ribosome dysfunction in osteoarthritis	17
Environmental triggers for connective tissue disease: the case of COVID-19 associated with dermatomyositis-specific autoantibodies	17
An update on autoantibodies in systemic lupus erythematosus	16
Biomarkers in systemic sclerosis: mechanistic insights into pathogenesis and treatment	16
Calcinosis in systemic sclerosis	16
Anti-HMGCR myopathy: clinical and histopathological features, and prognosis	15
Therapeutic advances in eosinophilic granulomatosis with polyangiitis	14
Low-dose computed tomography for axial spondyloarthritis: update on use and limitations	14
Janus kinase–signal transducers and activators of transcription cell signaling in Spondyloarthritis: rationale and evidence for JAK inhibition	14
Diagnostic delay in axial spondyloarthritis – a past or current problem?	14
Advances in osteoarthritis imaging	14
Polymyositis: does it really exist as a distinct clinical subset?	14
Differential diagnosis of necrotizing myopathy	13
Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance	13
Takayasu arteritis	13
Did COVID-19 impact osteoarthritis – clinical perspective?	12
The latest in systemic lupus erythematosus-accelerated atherosclerosis: related mechanisms inform assessment and therapy	12
Role of cellular senescence in the pathogenesis of systemic sclerosis	12
Antiphospholipid syndrome management: a 2023 update and practical algorithm-based approach	12
Review of publications evaluating opioid use in patients with inflammatory rheumatic disease	12
Is osteoarthritis a mitochondrial disease? What is the evidence	12
Update on the cellular pathogenesis of lupus	12
Gout and the COVID-19 pandemic	11
Fibromyalgia and centralized pain in the rheumatoid arthritis patient	11
A cursed goodbye kiss from severe acute respiratory syndrome-coronavirus-2 to its pediatric hosts: multisystem inflammatory syndrome in children	11
The transition from enthesis physiological responses in health to aberrant responses that underpin spondyloarthritis mechanisms	11
Glucocorticoid and opioid use in rheumatoid arthritis management	11
Acute and postacute COVID-19 outcomes for patients with rheumatoid arthritis: lessons learned and emerging directions 3 years into the pandemic	11
Scleroderma autoantibodies in guiding monitoring and treatment decisions	11
New lupus criteria: a critical view	10
Raynaud's phenomenon and digital ulcers: advances in evaluation and management	10
Immunopathogenesis of skin injury in systemic lupus erythematosus	10
Immune checkpoints and the multiple faces of B cells in systemic lupus erythematosus	10
Integrating genetic and social factors to understand health disparities in lupus	10
Intestinal dysbiosis in spondyloarthritis – chicken or egg?	9
Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence	9
Uveitis in Behçet disease - an update	9
Haematopoietic stem cell transplantation in paediatric rheumatic disease	9
Low-dose interleukin-2 therapy: a promising targeted therapeutic approach for systemic lupus erythematosus	9
Role of Janus Kinase inhibitors in rheumatoid arthritis treatment	9
Current views on lupus in children	9
Anti-MDA5 dermatomyositis: an update from bench to bedside	8
New mechanism-based approaches to treating and evaluating the vasculopathy of scleroderma	8
Insights into origins and specificities of autoantibodies in systemic sclerosis	8

Osteoarthritis gene therapy in 2022	8
An update on the microbiome in vasculitis	8
A treat-to-target approach is needed for Behçet's syndrome	8
An update on inflammation in antiphospholipid syndrome	8
Bone in osteoarthritis: imaging and interventions	7
The contribution of endothelial cells to tissue fibrosis	7
How can ultrasonography help in the management of CPPD? From diagnosis to clinical subset identification	7
Metabolic perturbations in systemic sclerosis	7
The use of mycophenolate mofetil area under the curve	7
Pathogenesis of vasculopathy in systemic sclerosis and its contribution to fibrosis	7
Epidemiology of osteoarthritis: literature update 2022–2023	7
Out of the shadow of interleukin-17A: the role of interleukin-17F and other interleukin-17 family cytokines in spondyloarthritis	7
Update on muscle imaging in myositis	7
Imaging techniques for assessment of vascular involvement in systemic sclerosis	7
Insights into the pathogenic role of neutrophils in systemic lupus erythematosus	7
Aortitis: an update	7
Dual-energy computed tomography in crystalline arthritis: knowns and unknowns	7
Treatment of juvenile localized scleroderma: current recommendations, response factors, and potential alternative treatments	6
Adipose tissue and adipose secretome in systemic sclerosis	6
Healthcare disparities in telemedicine for rheumatology care	6
Diagnosis and management of primary heart involvement in systemic sclerosis	6
Quo vadis reactive arthritis?	6
Updates in cutaneous manifestations of systemic vasculitis	6
Exploring challenges in the management and treatment of inclusion body myositis	6
Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease	6
Novel imaging techniques for sacroiliac joint assessment	6
Nonsteroidal anti-inflammatory drugs and cardiovascular disease risk in spondyloarthritis-spectrum diseases	6
Recent advances in elucidating the genetic basis of systemic sclerosis	6
Challenges of caring for transgender and gender diverse patients with rheumatic disease: presentation of seven patients and review of the literature	6
New therapeutic approaches in systemic lupus erythematosus	6
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria sets for three types of antineutrophilic cytoplasmic antibody-associated vasculitis	6
Is it time to move on from pelvic radiography as the first-line imaging modality for suspected sacroiliitis?	6
Optimizing reproductive health management in lupus and Sjogren's syndrome	5
Patient reported outcomes in systemic vasculitis	5
Pro and contra: is synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) a spondyloarthritis variant?	5
Coronavirus 2019: clinical and neuropathological aspects	5
Not all benign: disease course, complications, and sequalae of chronic recurrent multifocal osteomyelitis in children	5
Advances in the clinical use of hydroxychloroquine levels	5
The impact of omics research on our understanding of osteoarthritis and future treatments	5
Clinical features of multisystem inflammatory syndrome in children	5
The safety of glucocorticoids in the treatment of inflammatory rheumatic disease: new evidence	5
Human leucocyte antigen-B27 testing in clinical practice: a global perspective	5
Biologic disease-modifying antirheumatic drugs to treat multisystem inflammatory syndrome in children	5
Biomarkers of disease activity in dermatomyositis	5
Emerging cellular and immunotherapies for systemic sclerosis: from mesenchymal stromal cells to CAR-T cells and vaccine-based approaches	4
Beyond plaque psoriasis – pathogenesis and treatment of other psoriasis phenotypes	4
The complement system in antineutrophil cytoplasmic antibody-associated vasculitis: pathogenic player and therapeutic target	4
Contribution of keratinocytes to dermal fibrosis	4
Rheumatoid arthritis: prediction of future clinically-apparent disease, and prevention	4
Large language models and the future of rheumatology: assessing impact and emerging opportunities	4
The role of immunomodulatory medications in the treatment of COVID-19	4
Adherence to gout guidelines: where do we stand?	4
Medications for gout and its comorbidities: mutual benefits?	4
Emerging biologic therapies for systemic lupus erythematosus	4
Educational needs and challenges in axial spondyloarthritis	4
Defining and managing flares in axial spondyloarthritis	3
Intracranial vessel wall imaging	3
Janus kinase inhibitors: efficacy and safety	3
Rheumatology in the era of precision medicine: synovial tissue molecular patterns and treatment response in rheumatoid arthritis	3
Insights into molecular and clinical characteristics of very early systemic sclerosis	3
Update on autoantibodies and related biomarkers in autoimmune inflammatory myopathies	3
Regulatory T cells and systemic vasculitis	3
Cerebral vasculitis associated with drug abuse	3
Twenty years of clinical trials in axial spondyloarthritis: what can we learn for the future?	3
Epidemiology of systemic vasculitis	3
Physical exercise for the management of systemic autoimmune myopathies: recent findings, and future perspectives	3
Practical management strategies for benign hypermobility syndromes	3
Recent advances in the treatment of neuromyelitis optica spectrum disorders	3
Glucocorticoid-induced osteoporosis in premenopausal women: management for the rheumatologist	3
What is PFAPA syndrome? Genetic clues about the pathogenesis	3
Animal models of vasculitis	3